Brandon E Cohen1, Prashiela Manga2, Krysta Lin2, Nada Elbuluk3. 1. Department of Dermatology, Keck School of Medicine, University of Southern California, 830 South Flower Street, Suite 100, Los Angeles, CA, 90017, USA. 2. Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, NY, USA. 3. Department of Dermatology, Keck School of Medicine, University of Southern California, 830 South Flower Street, Suite 100, Los Angeles, CA, 90017, USA. nelbuluk@gmail.com.
Abstract
BACKGROUND: There has been a significant increase in the number and efficacy of therapies for advanced melanoma. Immunotherapies, such as anti-cytotoxic T-lymphocyte antigen-4 and programmed cell death-1 inhibitors, have improved the prognosis for patients with advanced melanoma. While spontaneous melanoma-associated vitiligo is a known phenomenon, the occurrence of melanoma-associated vitiligo following melanoma therapy is now recognized to associate with favorable outcomes. OBJECTIVE: The objective of this article is to provide a comprehensive literature review of melanoma-associated vitiligo and explore the insights these findings provide about the pathobiology of vitiligo and mechanisms underlying melanoma therapies. METHODS: PubMed and Science Direct databases were searched for studies pertaining to melanoma-associated vitiligo. The 36 studies reviewed included meta-analyses (n = 2), prospective cohort studies (n = 4), prospective observational studies (n = 3), retrospective studies (n = 12), case series (n = 2), and case reports (n = 13). RESULTS: The basic mechanisms underlying melanoma-associated vitiligo and vitiligo may be shared. Characterization of these mechanisms will identify new biomarkers and therapeutic targets for both melanoma and vitiligo. CONCLUSIONS: Co-opting the immune system to target tumor antigens highlights the potential overlap between anti-tumor immunity and autoimmunity. The development of vitiligo-like depigmentation in association with immunotherapy for melanoma may provide insights into both the immune response against melanoma as well as the pathogenesis of vitiligo.
BACKGROUND: There has been a significant increase in the number and efficacy of therapies for advanced melanoma. Immunotherapies, such as anti-cytotoxic T-lymphocyte antigen-4 and programmed cell death-1 inhibitors, have improved the prognosis for patients with advanced melanoma. While spontaneous melanoma-associated vitiligo is a known phenomenon, the occurrence of melanoma-associated vitiligo following melanoma therapy is now recognized to associate with favorable outcomes. OBJECTIVE: The objective of this article is to provide a comprehensive literature review of melanoma-associated vitiligo and explore the insights these findings provide about the pathobiology of vitiligo and mechanisms underlying melanoma therapies. METHODS: PubMed and Science Direct databases were searched for studies pertaining to melanoma-associated vitiligo. The 36 studies reviewed included meta-analyses (n = 2), prospective cohort studies (n = 4), prospective observational studies (n = 3), retrospective studies (n = 12), case series (n = 2), and case reports (n = 13). RESULTS: The basic mechanisms underlying melanoma-associated vitiligo and vitiligo may be shared. Characterization of these mechanisms will identify new biomarkers and therapeutic targets for both melanoma and vitiligo. CONCLUSIONS: Co-opting the immune system to target tumor antigens highlights the potential overlap between anti-tumor immunity and autoimmunity. The development of vitiligo-like depigmentation in association with immunotherapy for melanoma may provide insights into both the immune response against melanoma as well as the pathogenesis of vitiligo.
Authors: Peter D Boasberg; Dave S B Hoon; Lawrence D Piro; Maureen A Martin; Akhide Fujimoto; Timothy S Kristedja; Sandeep Bhachu; Xing Ye; Regina R Deck; Steven J O'Day Journal: J Invest Dermatol Date: 2006-08-31 Impact factor: 8.551
Authors: O Merimsky; Y Shoenfeld; E Baharav; M Altomonte; S Chaitchik; M Maio; S Ferrone; P Fishman Journal: Am J Clin Oncol Date: 1996-12 Impact factor: 2.339
Authors: Hansje-Eva Teulings; Karin J Willemsen; Iris Glykofridis; Gabrielle Krebbers; Lisa Komen; Marije W Kroon; E Helen Kemp; Albert Wolkerstorfer; J P Wietze van der Veen; Rosalie M Luiten; Esther P M Tjin Journal: Pigment Cell Melanoma Res Date: 2014-08-04 Impact factor: 4.693
Authors: Janny E Lommerts; Hansje-Eva Teulings; Khaled Ezzedine; Nanja van Geel; Anke Hartmann; Reinhart Speeckaert; Phyllis I Spuls; Albert Wolkerstorfer; Rosalie M Luiten; Marcel W Bekkenk Journal: J Am Acad Dermatol Date: 2016-10-04 Impact factor: 11.527
Authors: Hansje-Eva Teulings; Jacqueline Limpens; Sophia N Jansen; Aeilko H Zwinderman; Johannes B Reitsma; Phyllis I Spuls; Rosalie M Luiten Journal: J Clin Oncol Date: 2015-01-20 Impact factor: 44.544
Authors: P Fishman; E Azizi; Y Shoenfeld; B Sredni; G Yecheskel; S Ferrone; R Zigelman; S Chaitchik; S Floro; M Djaldetti Journal: Cancer Date: 1993-10-15 Impact factor: 6.860
Authors: P Quaglino; F Marenco; S Osella-Abate; N Cappello; M Ortoncelli; B Salomone; M T Fierro; P Savoia; M G Bernengo Journal: Ann Oncol Date: 2009-07-21 Impact factor: 32.976